QS Investors LLC trimmed its position in Edwards Lifesciences Corp (NYSE:EW) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,092 shares of the medical research company’s stock after selling 3,473 shares during the period. QS Investors LLC’s holdings in Edwards Lifesciences were worth $8,464,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of EW. Jefferies Group LLC boosted its position in shares of Edwards Lifesciences by 29.6% in the 4th quarter. Jefferies Group LLC now owns 77,687 shares of the medical research company’s stock worth $8,756,000 after buying an additional 17,756 shares in the last quarter. Compton Capital Management Inc. RI boosted its position in shares of Edwards Lifesciences by 84.4% in the 4th quarter. Compton Capital Management Inc. RI now owns 4,655 shares of the medical research company’s stock worth $525,000 after buying an additional 2,130 shares in the last quarter. JOYN Advisors Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $980,000. Gardner Lewis Asset Management L P purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $1,730,000. Finally, Fred Alger Management Inc. boosted its position in shares of Edwards Lifesciences by 610.3% in the 4th quarter. Fred Alger Management Inc. now owns 152,528 shares of the medical research company’s stock worth $17,191,000 after buying an additional 131,053 shares in the last quarter. Hedge funds and other institutional investors own 82.86% of the company’s stock.
EW has been the topic of several recent research reports. Evercore ISI initiated coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $174.00 price objective (up from $140.00) on shares of Edwards Lifesciences in a research report on Friday, February 2nd. BMO Capital Markets reiterated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research report on Friday, December 8th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $141.15.
Edwards Lifesciences Corp (NYSE EW) opened at $139.32 on Monday. Edwards Lifesciences Corp has a one year low of $91.30 and a one year high of $140.07. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The company has a market cap of $29,260.50, a PE ratio of 48.38, a PEG ratio of 2.06 and a beta of 0.56.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same quarter in the prior year, the company posted $0.75 EPS. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.49 earnings per share for the current year.
Edwards Lifesciences declared that its board has authorized a share buyback program on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: “QS Investors LLC Has $8.46 Million Position in Edwards Lifesciences Corp (EW)” was published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/12/qs-investors-llc-has-8-46-million-position-in-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.